Condition
Pityriasis Rubra Pilaris
Total Trials
6
Recruiting
0
Active
0
Completed
4
Success Rate
80.0%-7% vs avg
Key Insights
Highlights
Success Rate
80% trial completion
Clinical Risk Assessment
Based on trial outcomes
Low Risk
Score: 27/100
Termination Rate
16.7%
1 terminated out of 6 trials
Success Rate
80.0%
-6.6% vs benchmark
Late-Stage Pipeline
33%
2 trials in Phase 3/4
Results Transparency
75%
3 of 4 completed with results
Key Signals
3 with results80% success
Data Visualizations
Phase Distribution
6Total
P 1 (1)
P 2 (3)
P 4 (2)
Trial Status
Completed4
Not Yet Recruiting1
Terminated1
Trial Success Rate
80.0%
Benchmark: 86.6%
Based on 4 completed trials
Clinical Trials (6)
Showing 6 of 6 trials
NCT06444399Phase 2CompletedPrimary
Deucravacitinib (BMS-986165) for Pityriasis Rubra Pilaris
NCT07497620Phase 4Not Yet RecruitingPrimary
Bimzelx (Bimekizumab) For The Treatment Of Adult Onset PRP
NCT03975153Phase 2CompletedPrimary
Guselkumab in the Treatment of Pityriasis Rubra Pilaris (PRP)
NCT03342573Phase 1CompletedPrimary
Cosentyx (Secukinumab) for the Treatment of Adult Onset Pityriasis Rubra Pilaris
NCT03485976Phase 2CompletedPrimary
Ixekizumab in the Treatment of Pityriasis Rubra Pilaris (PRP)
NCT00815633Phase 4TerminatedPrimary
A Pilot Study of Alefacept for the Treatment of Pityriasis Rubra Pilaris
Showing all 6 trials